A practical reference on Reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-19 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
58. Dermatol Online J. 2018 May 15;24(5):13030/qt2gz9f9jk. A glimpse into the underground market of melanotan. Callaghan Iii DJ(1). Author information: (1)Department of Dermatology, Boston Medical Center, Boston, Massachusetts. danieljcallaghan3@gmail.com. Melanotan-I and melanotan-II are alpha-melanocyte stimulating hormone (a-MSH) analogues that can be purchased illicitly online with relative ease and are injected subcutaneously to stimulate a tan. Little is known about the use of these unregulated substances. An observational survey was posted to an online forum in which participants share their experiences using melanotan-I or melanotan-II. Users were asked to complete this voluntary, anonymous survey, which had questions focusing on motivation and hesitation for and against using melanotan, difficulty in acquiring it, and plans for continuing to use melanotan in the future.
Type I: skin, tendon, vasculature, organs, bone (main component of the organic part of bone) Type II: cartilage (main collagenous component of cartilage) Type III: reticulate (main component of reticular fibers), commonly found alongside type I Type IV: forms basal lamina, the epithelium-secreted layer of the basement membrane Type V: found in the skin (especially around hair follicles and sweat glands) and research suggests it is involved in wound healing and bridging the dermis and epidermis. Also found in the placenta.
== Synthesis == In the radiopharmaceutical industry, fluorine-18 is made using either a cyclotron or linear particle accelerator to bombard a target, usually of natural or enriched [18O]water with high energy protons (typically ~18 MeV). The fluorine produced is in the form of a water solution of [18F]fluoride, which is then used in a rapid chemical synthesis of various radiopharmaceuticals. This must be done after the fluorine is produced, as chemical bonds would be destroyed by the production (radiolysis).
== References == Aldose reductase inhibitor for treatment of diabetic complications. Prepn (stereo unspec): M. Kurono, et al., EP 193415; eidem, US 4740517 (1986, 1988 both to Sanwa) Prepn of isomers: T. Yamaguchi et al., Arzneim.-Forsch. 44, 344 (1994) Pharmacological profile: K. Mizuno et al. in Current Concepts of Aldose Reductase and Its Inhibitions, N. Sakamoto et al., Eds. (Elsevier, Amsterdam, 1990) pp 89–96. Configuration and crystal structure of complex with aldose reductase: M. Oka et al., J. Med. Chem. 43, 2479 (2000). Clinical efficacy in diabetic peripheral neuropathy: N. Hotta et al., Diabetes Care 24, 1776 (2001). Clinical suppression of sorbitol accumulation in erythrocytes of diabetic patients: T. Asano et al., J. Diabetes Complications 16, 133 (2002); eidem, ibid. 18, 336 (2004). Review of clinical development: N. Giannoukakis, Curr. Opin. Invest. Drugs 4, 1233-1239 (2003).
Sources: pubmed.ncbi.nlm.nih.gov
Though rare, estimates of the prevalence of vaginal cuff dehiscence after hysterectomy are estimated and reported to be between 0.14 and 4.1% per the American College of Obstetricians and Gynecologists (ACOG). If the vaginal cuff is compromised, vaginal evisceration can occur with the small intestine protruding out through the vagina.
The Spartanburg Pellagra Hospital in Spartanburg, South Carolina, was the first facility in the United States dedicated to discovering the cause of pellagra. It was established in 1914 with a special Congressional appropriation to the U.S. Public Health Service and set up primarily for research. In 1915, Dr. Joseph Goldberger, assigned to study pellagra by the surgeon general of the United States, showed it was linked to diet by observing the outbreaks of pellagra in orphanages and mental hospitals. Goldberger noted that children between the ages of 6 and 12 (but not older or younger children at the orphanages) and patients at the mental hospitals (but not doctors or nurses) were the ones who seemed most susceptible to pellagra. Goldberger theorized that a lack of meat, milk, eggs, and legumes made those particular populations susceptible to pellagra. By modifying the diet served in these institutions with "a marked increase in the fresh animal and the leguminous protein foods," Goldberger was able to show that pellagra could be prevented. By 1926, Goldberger established that a diet that included these foods, or a small amount of brewer's yeast, prevented pellagra. Goldberger experimented on 11 prisoners (one was dismissed because of prostatitis). Before the experiment, the prisoners were eating the prison fare fed to all inmates at Rankin Prison Farm in Mississippi. Goldberger started feeding them a restricted diet of grits, syrup, mush, biscuits, cabbage, sweet potatoes, rice, collards, and coffee with sugar (no milk).
C1 domains and phorbol esters. C2 domains bind phosphatidylserine, phosphatidylcholine or PtdIns(3,4)P2 or PtdIns(4,5)P2. Pleckstrin homology domains, PX domains, and Tubby domains bind different phosphoinositides FYVE domains are more specific for PtdIns3P. ENTH domains bind PtdIns(3,4)P2 or PtdIns(4,5)P2. ANTH domain binds PtdIns(4,5)P2. Proteins from ERM (ezrin/radixin/moesin) family bind PtdIns(4,5)P2. Other phosphoinositide-binding proteins include phosphotyrosine-binding domain and certain PDZ domains. They bind PtdIns(4,5)P2. Discoidin domains of blood coagulation factors ENTH, VHS and ANTH domains
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.